A secondary analysis of the phase 3 KEYNOTE-716 trial finds that adjuvant Keytruda improves recurrence-free survival without increasing the risk of new primary melanoma and may reduce non-melanoma ...

The results show that those with low vitamin D levels had a significantly higher risk of hospitalization related to respiratory tract infection compared with those whose 25 (OH)D levels were 75 nmol/L ...

Cost-effectiveness is highly price-sensitive; lower U.S. prices, particularly approaching European levels, shift semaglutide toward favorable value rather than a binary go/no-go determination. Patient ...

Risant’s CEO Jaewon Ryu discusses some of the early success of bringing a set of Kaiser Permanente’s value-based care ...

In the first segment of a video interview with MHE, the CEO of Risant Health discusses the role of scale in following ...

Predictable reimbursement is a primary operational determinant of biosimilar longevity in practices, frequently outweighing ...

Becoming a qualified treatment center can take six to 18 months, according to Mahmoudjafari. Some institutions begin ...

Ambient note-generation and encounter-focused summarization can meaningfully decrease pre-visit review and post-visit documentation time, enabling clinicians to reallocate effort toward direct patient ...

In an hour and 48-minute speech that set the record for length for the State of the Union address, President Donald Trump spent less than five minutes on healthcare issues.

The role of the pharmacist, managed care pharmacist job satisfaction and artificial intelligence were among the topics that Susan A. Cantrell, CEO of the Academy of Managed Care Pharmacy, discussed ...

Lung cancer cells are able to take advantage of a person’s immune system, specifically T cells, to protect the tumor, according to new research recently published in Cancer Immunology Research.

“GLP‑1s have effectively created a third pillar of pharmacy spend and most employers don't yet have a mature playbook to manage it,” Conway said, adding that over half of employers now cite GLP‑1s as ...